Abstract Coronavirus disease 2019 (COVID-19) outbreak has become a global public health
emergency and has led to devastating results. Mounting evidence proposes that the disease …

Acute respiratory distress syndrome (ARDS) is a heterogeneous cause of respiratory failure
that has a rapid onset, a high mortality rate, and for which there is no effective …

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) or pulmonary fibrosis (PF)
has been regarded as a global health issue with high mortality and limited drug therapy …

Acute lung injury (ALI) is a life-threatening disease that has received considerable critical
attention in the field of intensive care. This study aimed to explore the role and mechanism of …

Dexamethasone (DEXA) is a potent corticosteroid, commonly used for treating inflammatory,
hypersensitive and allergic conditions. It is administered to birds with tumours. Many studies …

Background The severity of COVID-19 is associated with an elevated level of a variety of
inflammatory mediators. Increasing evidence suggests that the Th17 response contributes to …

The acute exudative phase of acute respiratory distress syndrome (ARDS), a severe form of
respiratory failure, is characterized by alveolar damage, pulmonary oedema, and an …

Abstract Background Dexamethasone (Dexa) has been recently found to exert an analgesic
effect, whose action is closely related to IL-8. However, whether dexamethasone induces …

Background There are no direct disease-modifying pharmacologic therapies for acute
respiratory distress syndrome (ARDS). 1 The mainstays of ARDS management are …

The COVID-19 pandemic has prompted the exploration of effective treatment options, with
dexamethasone emerging as a key corticosteroid for severe cases. This review evaluates …